Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oncolytic vaccinia viruses (OVVs) are genetically engineered viruses designed to selectively infect, replicate within, and destroy tumor cells. OVVs induce oncolysis through multiple mechanisms, including direct cell lysis, disruption of tumor vasculature, and the activation of anti-tumor immune responses. Genetic modifications enhance safety and efficacy by restricting replication to tumor cells and expressing immunostimulatory transgenes. OVVs are being investigated in clinical trials as monotherapies and in combination with other cancer treatments.
Selective infection and replication in tumor cells, leading to direct oncolysis, disruption of tumor vasculature, and stimulation of anti-tumor immune responses.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaccinia Virus (Oncolytic) (OVV).